Targeting of podoplanin with lectin for use in the prevention and treatment of cancer
Lectin compositions and methods for reducing tumor cell growth and preventing or treating cancer are provided.
1. A method for reducing tumor cell growth and migration comprising contacting a tumor cell with an effective amount of a lectin that binds sialic acid consisting of an amino acid sequence as set forth in SEQ ID NO:23, thereby reducing tumor cell growth and migration.
2. A method for reducing tumor size and vascularization in a subject comprising administering to a subject in need thereof an isolated lectin that binds sialic acid consisting of an amino acid sequence as set forth in SEQ ID NO:23 thereby decreasing tumor size and vascularization.
3. The method of claim 2 , wherein the lectin is administered orally.
4. A method for treating cancer comprising administering to a subject in need thereof an effective amount of an isolated lectin that binds sialic consisting of an amino acid sequence as set forth in SEQ ID NO:23 thereby treating the subject's cancer.
5. The method of claim 4 , wherein the lectin is administered orally.
6. A pharmaceutical composition comprising an isolated lectin that binds sialic acid wherein the lectin consists of the amino acid sequence as set forth in SEQ ID NO:23 in a mixture with a pharmaceutically acceptable carrier.
7. The pharmaceutical composition of claim 6 , wherein said composition is formulated for oral administration.
8. A kit comprising an isolated lectin that binds sialic acid wherein the lectin consists of the amino acid sequence as set forth in SEQ ID NO:23.
9. The kit of claim 8 further comprising at least one suitable component selected from the group consisting of a pharmaceutically acceptable carrier, measuring device, a buffer, a diluent, a filter, a package insert with instructions for use, and any combinations thereof.
10. A method of targeting Pdpn expressed on a cell comprising orally administering to a subject in need thereof a composition comprising sufficient amounts of an isolated lectin consisting of the amino acid sequence set forth in SEQ ID NO:23, allowing sufficient amount of time for said lectin to bind cellular Pdpn thereby forming a lectin-Pdpn molecular complex comprising at least a portion of the amino acid sequence set forth in SEQ ID NO:23 and wherein formation of said complex inhibits the activity of Pdpn.
11. The method of claim 10 , wherein formation of said complex modifies the cells behavior as compared to cells not exposed to said lectin.
12. The method of claim 10 , wherein the subject in need thereof is suffering from cancer.
13. The method of claim 12 , wherein the cancer is selected from the group consisting of carcinoma, leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, and prostate cancer.
14. The method of claim 10 , wherein the lectin is administered orally.